The Latest Cardiac and Vascular News
REDWOOD CITY, Calif., June 21, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that its Ocelot image-guided chronic total occlusion (CTO) crossing device was featured in a live case on June 19th at Complex Cardiovascular Catheter Therapeutics (C3) 2018 in Orlando, Florida. Ocelot combines […]
REDWOOD CITY, Calif., June 14, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the initiation of the SCAN study, a post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. OCT is a […]
REDWOOD CITY, Calif., June 13, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Mark Weinswig will join the Company, and serve in the role of Chief Financial Officer (CFO) effective June 25, 2018. Mr. Weinswig will succeed Matt […]
REDWOOD CITY, Calif., May 30, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions and posters highlighting the company’s Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference taking place this week in New Orleans, Louisiana, from Tuesday, May […]
REDWOOD CITY, Calif., May 29, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that it will be presenting at the 8th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Bel Air, California. The conference will be held on June 4-6, 2018. […]
REDWOOD CITY, Calif., May 23, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its next generation Pantheris® Lumivascular atherectomy system, the first-ever image-guided atherectomy device for the treatment […]
REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the first quarter ended March 31, 2018. First Quarter and Recent Highlights Revenue of $1.8 million for the first quarter of 2018 Announced treatment of first patients globally […]
REDWOOD CITY, Calif., April 30, 2018 – Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that its next generation Pantheris® Lumivascular atherectomy system with extended nosecone was featured in a live case transmission at Charing Cross Symposium (CX) 2018 held in London, England. Charing Cross had more than 4,000 vascular […]
REDWOOD CITY, Calif., March 02, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced it has regained compliance with Nasdaq listing requirements. In a letter dated March 1, 2018, Nasdaq informed the Company that it has achieved compliance with the minimum bid price rule, […]
Secured Lenders Convert $38 Million of Debt into Equity REDWOOD CITY, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) — Avinger, Inc.(NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the pricing of an underwritten public offering of Series B convertible preferred stock, together with warrants, for gross proceeds of $18.0 million, prior […]
